NASDAQ:IRIX - IRIDEX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: -10.55 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.59
▼ -0.16 (-2.78%)
1 month | 3 months | 12 months
Get New IRIDEX Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRIX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.00
▼ -10.55% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for IRIDEX in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a -10.55% upside from the last price of $5.59.
Buy
The current consensus among 2 contributing investment analysts is to buy stock in IRIDEX.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021Roth CapitalBoost Price TargetBuy$5.50 ➝ $6.00High
i
5/12/2020Stifel NicolausLower Price TargetBuy$5.00 ➝ $4.00High
i
3/16/2020Roth CapitalReiterated RatingBuyMedium
i
Rating by S. Henry at Roth Capital
2/5/2019Roth CapitalReiterated RatingBuyHigh
i
Rating by S. Henry at Roth Capital
1/4/2019Stifel NicolausLower Price TargetBuy ➝ Buy$9.00 ➝ $7.00Low
i
10/26/2018Stifel NicolausInitiated CoverageBuy$9.00Medium
i
10/12/2018Roth CapitalReiterated RatingBuy$10.00High
i
Rating by David Solomon at Roth Capital
11/3/2017Roth CapitalReiterated RatingBuy ➝ Buy$13.00N/A
i
Rating by S. Henry at Roth Capital
12/21/2016Roth CapitalInitiated CoverageBuy$20.00N/A
i
1/26/2016Singular ResearchInitiated CoverageBuy$11.50N/A
i
(Data available from 1/20/2016 forward)
IRIDEX logo
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $5.59
$5.39
$5.85

50 Day Range

MA: $2.57
$1.62
$5.75

52 Week Range

Now: $5.59
$1.22
$6.25

Volume

366,202 shs

Average Volume

1,459,618 shs

Market Capitalization

$77.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of IRIDEX?

The following Wall Street analysts have issued reports on IRIDEX in the last twelve months: Roth Capital, Stifel Nicolaus, and Zacks Investment Research.

What is the current price target for IRIDEX?

2 Wall Street analysts have set twelve-month price targets for IRIDEX in the last year. Their average twelve-month price target is $5.00, suggesting a possible downside of 10.6%. Roth Capital has the highest price target set, predicting IRIX will reach $6.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $4.00 for IRIDEX in the next year.

What is the current consensus analyst rating for IRIDEX?

IRIDEX currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IRIX will outperform the market and that investors should add to their positions of IRIDEX.

What other companies compete with IRIDEX?

How do I contact IRIDEX's investor relations team?

IRIDEX's physical mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider's listed phone number is 650-940-4700 and its investor relations email address is investors@iridex.com. The official website for IRIDEX is www.iridex.com.